Skip to main content
TipRanks
Go Ultimate75% OFF

Whitehawk Therapeutics (3350) Q4 2024 Earnings Report

1 Followers

DE:3350 Q4 2024 EPS Results

Actual EPS
-EUR 0.61
Consensus EPS
-EUR 0.27
Beat/Miss
Missed by -EUR 0.34
One Year Ago EPS
-EUR 0.54

DE:3350 Q4 2024 Revenue Results

Actual Revenue
EUR 6.54M
Expected Revenue
EUR 6.72M
Beat/Miss
Missed by -EUR 177.17K
YoY Revenue Growth
+14.43%

Earnings Announcement Details

Quarter
Q4 2024
Date
03/18/2025
Time
After Close
Conference Call
Tuesday, March 18, 2025
DE:3350 Upcoming Earnings

Whitehawk Therapeutics's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q4 2024 Earnings Call Audio

DE:3350 Q4 2024 Earnings Call
0:00 / 0:00

Q4 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q4 2024 Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 18, 2025|% Change Since:45.13%|
Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment with significant strategic transformations, a promising pipeline of ADC therapies, and strong financial positioning. However, there are concerns about increased R&D expenses and net losses, which are common in early biotech transitions.

Company Guidance

In the earnings call for the fourth quarter and full year 2024, Whitehawk Therapeutics provided guidance on their transformative shift from Aadi Biosciences to an ADC-focused company. The key metrics highlighted include a $100 million PIPE financing and the divestiture of FYARRO, which resulted in a financial position of $170 million to $180 million in cash and equivalents, expected to fund operations into 2028. The company reported FYARRO net product sales of $7.2 million for the fourth quarter, marking a 14% increase from the previous year, and $26 million for the full year, a 7% rise from 2023. Research and development expenses increased to $14.3 million for the quarter and $51 million for the year, primarily due to ADC program acquisitions. Whitehawk plans to file three Investigational New Drug (IND) applications within 15 months for their ADC candidates, targeting PTK7, MUC16, and SEZ6, with anticipated Phase 1 trials in several high-potential cancer indications.

  • Transformation and Strategic TransactionsWhitehawk Therapeutics was launched from Aadi Biosciences, including in-licensing 3 ADCs from Wuxi Biologics, divestiture of FYARRO to Kaken Pharmaceuticals, and $100 million pipe financing, approved by stockholders.
  • Advanced ADC PlatformWhitehawk is rapidly progressing a multi-asset portfolio of advanced ADC therapy, leveraging a platform with minimal off-target toxicity, greater stability, and higher therapeutic index compared to first-generation predecessors.
  • Financial PositionEnded 2024 with $47.2 million in cash and expect $170-$180 million after transactions, funding operations into 2028.
  • FYARRO Sales GrowthFYARRO net product sales were $7.2 million for Q4, representing 14% growth over the prior year quarter. Full-year sales were $26 million, an increase of 7% over 2023.

DE:3350 Earnings History

DE:3350 earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 18, 20272026 (Q4)-0.20--0.31――
Nov 09, 20262026 (Q3)-0.19-0.21-0.2411.54% (+0.03)
Aug 06, 20262026 (Q2)-0.27-0.18-0.6973.68% (+0.51)
May 07, 20262026 (Q1)-0.32-0.291.65-117.49% (-1.94)
Mar 12, 20262025 (Q4)-0.44-0.31-0.6149.25% (+0.30)
Nov 06, 20252025 (Q3)0.06-0.24-0.4243.48% (+0.18)
Aug 07, 20252025 (Q2)0.75-0.69-0.49-40.74% (-0.20)
May 08, 20252025 (Q1)-0.421.65-0.61369.12% (+2.27)
Mar 18, 20252024 (Q4)-0.27-0.61-0.54-11.67% (-0.06)
Nov 06, 20242024 (Q3)-0.41-0.42-0.5423.33% (+0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed